MX9804009A - Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8. - Google Patents

Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.

Info

Publication number
MX9804009A
MX9804009A MX9804009A MX9804009A MX9804009A MX 9804009 A MX9804009 A MX 9804009A MX 9804009 A MX9804009 A MX 9804009A MX 9804009 A MX9804009 A MX 9804009A MX 9804009 A MX9804009 A MX 9804009A
Authority
MX
Mexico
Prior art keywords
receptor
inhibition
tumor growth
antisense oligonucleotides
oligonucleotides
Prior art date
Application number
MX9804009A
Other languages
English (en)
Inventor
Zbigniew Pietrzkowski
Dariusz Cieslak
Gordana Olbina
Original Assignee
Icn Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals
Publication of MX9804009A publication Critical patent/MX9804009A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen oligonucleotidos que son efectivos para inhibir el crecimiento, la metástasis y/o la angiogénesis de tumores, incluyendo particularmente melanoma y/o cáncer pulmonar. También se proveen métodos para utilizar estos oligonucleotidos en el tratamiento de enfermedades.
MX9804009A 1995-11-21 1998-05-20 Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8. MX9804009A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56130295A 1995-11-21 1995-11-21

Publications (1)

Publication Number Publication Date
MX9804009A true MX9804009A (es) 1998-11-29

Family

ID=24241411

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9804009A MX9804009A (es) 1995-11-21 1998-05-20 Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.

Country Status (14)

Country Link
US (2) US5849903A (es)
EP (1) EP0879241A4 (es)
JP (1) JPH11507245A (es)
KR (1) KR19990071523A (es)
CN (1) CN1202900A (es)
AU (1) AU708096B2 (es)
CA (1) CA2236825A1 (es)
CZ (1) CZ154898A3 (es)
EA (1) EA000841B1 (es)
MX (1) MX9804009A (es)
PL (1) PL326674A1 (es)
SI (1) SI9620122A (es)
SK (1) SK66098A3 (es)
WO (1) WO1997019097A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033977A1 (en) * 1990-08-14 2004-02-19 Bennett C. Frank Oligonucleotide modulation of cell adhesion
KR100530278B1 (ko) * 1997-02-28 2006-04-06 동국제약 주식회사 아시아트산 유도체를 유효성분으로 하는 간 보호 및치료제
US7332270B1 (en) 1997-03-24 2008-02-19 Urocor, Inc. Diagnosis of disease state using mRNA profiles in peripheral leukocytes
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
EP2009109A1 (en) 1998-01-12 2008-12-31 Pedro Jose G protein-related kinase mutants in essential hypertension
US20040043948A1 (en) * 2001-09-24 2004-03-04 Isis Pharmaceuticals Inc. Antisense modulation of interleukin 8 expression
JP2003515525A (ja) * 1999-04-06 2003-05-07 イースト カロライナ ユニバーシティ 気管支収縮、肺炎、アレルギーおよびサーファクタント枯渇と関連する気道障害を治療するための、低アデノシンアンチセンスオリゴヌクレオチド、その組成物、キットならびにその方法
EP1238070B1 (en) * 1999-12-13 2007-08-15 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
WO2001047518A1 (en) * 1999-12-23 2001-07-05 Childrens Hospital Los Angeles Research Institute Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant emap ii
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
AU9684601A (en) 2000-10-12 2002-04-22 Univ Rochester Compositions that inhibit proliferation of cancer cells
WO2002066070A1 (fr) * 2001-02-20 2002-08-29 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation associe
IL159722A0 (en) * 2001-07-10 2004-06-20 Oligos Etc Inc Pharmaceutical compositions containing oligonucleotides
EP2363405A1 (en) 2002-02-06 2011-09-07 Stasys Technologies, Inc. Anti-infarction molecules
EP1534729A2 (en) * 2002-02-26 2005-06-01 University of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
CA2495478A1 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
CN100537761C (zh) * 2003-11-07 2009-09-09 中国人民解放军军事医学科学院放射医学研究所 反义寡核苷酸,含它们的药物组合及其用于治疗癌症的用途
EP1744761A4 (en) * 2004-04-28 2010-01-13 Molecules For Health Inc METHOD FOR THE TREATMENT OR PREVENTION OF RESTENOSIS AND OTHER PROLIFERATIVE VASCULAR DISORDER
AU2006226733C9 (en) 2005-03-23 2019-03-14 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
EP2392645A1 (en) 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
CN100376680C (zh) * 2005-11-01 2008-03-26 暨南大学 双重靶效应基因嵌合重组体及其构建方法和应用
EP2560001B1 (en) 2006-09-21 2016-04-13 University of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
EP2104516B1 (en) 2006-11-01 2015-01-07 University of Rochester Methods and compositions related to the structure and function of apobec3g
US7994130B2 (en) 2006-12-11 2011-08-09 University Of Utah Research Foundation Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability
CN101275134B (zh) * 2007-04-20 2010-06-02 清华大学深圳研究生院 治疗乳腺癌的药物及其专用反义寡核苷酸
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
EP2853897A1 (en) 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
WO2010019963A2 (en) 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
EP2370080A1 (en) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
US10441637B2 (en) 2013-11-21 2019-10-15 Sena Research, Inc. Methods for structural determination of selenium derivatized nucleic acid complexes
EP3189069A4 (en) 2014-07-31 2018-03-07 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
CN109563516B (zh) 2016-07-28 2023-10-27 雷杰纳荣制药公司 Gpr156变体及其用途
AU2017306422A1 (en) 2016-08-03 2019-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
WO2018136702A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
CA3065938A1 (en) 2017-06-05 2018-12-13 Regeneron Pharmaceuticals, Inc. B4galt1 variants and uses thereof
JP7237064B2 (ja) 2017-09-06 2023-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 単一免疫グロブリンインターロイキン－１受容体関連（ｓｉｇｉｒｒ）変異型及びその使用
WO2019051033A1 (en) 2017-09-07 2019-03-14 Regeneron Pharmaceuticals, Inc. VARIANTS OF MEMBER 1 OF SOLUT TRANSPORTER FAMILY 14 (SLC14A1) AND USES THEREOF
US12016314B2 (en) 2017-09-08 2024-06-25 Ohio State Innovation Foundation MicroRNA inhibitor therapy in systemic lupus erythematosus
KR20240125690A (ko) 2017-10-11 2024-08-19 리제너론 파마슈티칼스 인코포레이티드 Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해
RU2020115869A (ru) 2017-10-16 2021-11-19 Ридженерон Фармасьютикалз, Инк. Варианты корнулина (crnn) и их применение
US10752682B2 (en) 2017-11-01 2020-08-25 Nantbio, Inc. Anti-IL8 antibodies
US11957687B2 (en) 2019-07-02 2024-04-16 Regeneron Pharmaceuticals, Inc. Modulators of HSD17B13 and methods of use thereof
WO2024173343A1 (en) 2023-02-14 2024-08-22 Regeneron Pharmaceuticals, Inc. Compounds targeting hydroxysteroid 17-beta dehydrogenase (hsd17b) and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides

Also Published As

Publication number Publication date
SK66098A3 (en) 1998-11-04
US5849903A (en) 1998-12-15
CA2236825A1 (en) 1997-05-29
EA000841B1 (ru) 2000-04-24
AU708096B2 (en) 1999-07-29
SI9620122A (sl) 1999-04-30
CZ154898A3 (cs) 1998-09-16
AU1053197A (en) 1997-06-11
CN1202900A (zh) 1998-12-23
PL326674A1 (en) 1998-10-12
US6017898A (en) 2000-01-25
KR19990071523A (ko) 1999-09-27
WO1997019097A1 (en) 1997-05-29
EA199800391A1 (ru) 1999-10-28
EP0879241A4 (en) 2000-04-19
JPH11507245A (ja) 1999-06-29
EP0879241A1 (en) 1998-11-25

Similar Documents

Publication Publication Date Title
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
IL143921A (en) Compositions for the treatment and prevention of tumor-related disorders, for inhibiting tumor growth and for inhibiting tumor metastasis
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
PT1187632E (pt) Tratamento com anticorpos anti-erbb2
PT971585E (pt) Compostos tetraciclina no tratamento de certos tipos de cancros
NO970039D0 (no) Fremgangsmåte for inhibering av cancer matastaser ved oral administrering av opplöselig modifisert sitruspektin
WO2002092854A3 (en) Genes expressed in breast cancer as prognostic and therapeutic targets
IL134445A0 (en) A method of preventing or treating estrogen-dependent diseases and disorders
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
ATE234354T1 (de) Zusammensetzung aus brustkrebszellen, die mit einem gegen den rezeptor für insulin-ähnlichen wachstumsfaktor gerichteten antisens- oligonukleotidbehandelt worden sind.
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
WO2000032765A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
ATE406160T1 (de) Verwendung von anastrozol zur behandlung von postmenopausalen frauen mit frühzeitigem brustkrebs
MXPA02001204A (es) Compuestos calciliticos.
WO2002032429A3 (en) Use of inhibitors of progesterone receptor for treating cancer
WO2002047710A3 (en) Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer
IL189502A0 (en) Methods and compositions for inhibiting neoplastic cell growth
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
DE69935156D1 (de) hCG THERAPIE ZUR BEHANDLUNG VON METASTATISCHEM BRUSTKREBS
ZA200203166B (en) Treatment of cancer.
EP0925074A4 (en) REVERSE OF A CANCER PHENOTYPE BY EXPRESSION INHIBITING PROSTATATUM-INDUCING GENES
IL109633A (en) Tnf receptor promoter
WO2001036048A8 (en) Phorboxazole derivatives for treating cancer
WO2002008456A3 (de) Verfahren zur identifizierung metastasierender tumorzellen
WO2001079505A3 (en) INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY